| |
Pakistan 2009
(n=109 ) |
Partin 2007*
(n= 5730 ) |
| CLINICAL STAGE |
|
|
| T1c |
33 (30) |
4419 (77) |
| T2a |
25 (23) |
998(17) |
| T2b/T2c |
51 (47) |
313 (6) |
| PSA (ng/ml) Δ |
|
|
| 0-2.5 |
3 (3) |
452 (8) |
| 2.6-4.0 |
2 (2) |
946 (17) |
| 4.1-6.0 |
15 (14) |
1994 (35) |
| 6.1-10.0 |
34 (31) |
1671 (29) |
| >10.0 |
55 ( 50) |
667 (12) |
| BIOPSY GLEASON SUM |
|
|
| 5-6 |
63 (58) |
4402 (77) |
| 3+4=7 |
23 (21) |
816 (14) |
| 4+3=7 |
11 (10) |
348 (6) |
| 8-10 |
12 ( 11) |
164 (3) |
| PATHOLOGICAL STAGE |
|
|
| Organ confined |
63 (58) |
4204 (73) |
| Extra prostatic extension |
9 (8) |
1276 (22) |
| Seminal vesicle involvement |
24 (22) |
180 (3) |
| Lymph node metastasis |
13 (12) |
70 (1) |
* Makarov et al. [13]
Δ Abbot Hybritech Assay |